

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/668,482	09/25/2000	P. Martin Petkovich	57600/00035	3039
7590 05/25/2004			EXAMINER	
JOHN C. HUNT			SLOBODYANSKY, ELIZABETH	
TORY'S LLP SUITE3000, 79 WELLINGTON STREET WEST			ART UNIT	PAPER NUMBER
BOX 270, TORONTO-DOMINION CENTRE			1652	
TORONTO, MSL1A9 CANADA			DATE MAILED: 05/25/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Advisory Action	09/668,482	PETKOVICH ET AL.
Advisory Action	Examiner	Art Unit
	Elizabeth Slobodyansky, PhD	1652
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence address
THE REPLY FILED 29 April 2004 FAILS TO PLACE THE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	avoid abandonment of this appli 1) a timely filed amendment wh	cation. A proper reply to a ich places the application in
PERIOD FOR RE	PLY [check either a) or b)]	•
a) The period for reply expires <u>4</u> months from the mailing date of	f the final rejection.	
b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of exten 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moterned patent term adjustment. See 37 CFR 1.704(b).	an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THate on which the petition under 37 CFR 1, sion and the corresponding amount of the distallutory period for reply originally set in	of the final rejection. IE FINAL REJECTION. See MPEP  136(a) and the appropriate extension fee e fee. The appropriate extension fee under the final Office action; or (2) as set forth in
1 A Notice of Appeal was filed on Appellant 37 CFR 1.192(a), or any extension thereof (37 CF		
2. The proposed amendment(s) will not be entered be		
(a) X they raise new issues that would require furth	er consideration and/or search	(see NOTE below):
(b) they raise the issue of new matter (see Note)		(655 115 12 25.5),
(c) ☐ they are not deemed to place the application	·	terially reducing or simplifying the
issues for appeal; and/or	in bottor form for appear by the	tenenty reducing or empiritying the
(d) they present additional claims without cance	ling a corresponding number of	finally rejected claims.
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following rejection	ction(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a s	separate, timely filed amendment
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: See		sidered but does NOT place the
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>83,90 and 113-161</u> .		
Claim(s) withdrawn from consideration:		
8. The drawing correction filed on is a) app	proved or b) disapproved by	the Examiner.
9.  Note the attached Information Disclosure Stateme		
10.⊠ Other: Interview Summary 18 May 2004		S. Shoody one
	6	Elizabeth Slobodyansky, PhD Primary Examiner Art Unit: 1652

Continuation of 2. NOTE: the scope of the claims has been changed including changes in dependency requiring further consideration and/or search.

Continuation of 5. does NOT place the application in condition for allowance because: for the reasons of record in view of NON-ENTRY of the amendment.

If the amendment were entered, it would overcome the following rejection(s): 112, 1st new matter, of claims 83, 90, 113-157; 112, 1st enablement of claims 116, 120-128, 131-139, 142-147, 149-155, 157, 160, 161; 112, 2nd of claims 83, 90, 113-129, 131-140, 142-148, 150-156, 158-161.

However, claims 114, 115, 118 and 119 would be rejected under 112, 2<sup>nd</sup> because taken into account the homology between SEQ ID NO:3 and SEQ ID NO:5 or SEQ ID NO:3 and SEQ ID NO:5 or SEQ ID NO:31 under hybridization conditions comprising a wash in 0.2 x SSC at 50 C. If such nucleotide sequences do exist, their representative species are not described in the specification requiring 112, 1<sup>st</sup> rejections. Furthermore, conceding to the assertion that SEQ ID NO:5 hybridizes to SEQ ID NO:3 under the claimed conditions (see interview summary), would require 102 (b) rejection of claims 83, 90 and 113-157 similar to the one made in the Office action of 2/13/03. This is because the art teaches human protein that is inherently encoded by SEQ ID NO:5 that hybridizes to SEQ ID NO:3 under conditions comprising a wash in 0.2 X SSC at 50 C. Thus, 103 rejection would be converted to 102 rejection absent the new matter limitation.

Claim 129, dependent from canceled claim 128, would be rejected under 112, 2<sup>nd</sup> as incomplete.

Further, the examiner does not agree that Figs. 11(a,b) provide support for claims 157-161 because there are no defined numbers on the axes and calculations can be made only approximately, i.e. "about six fold", for example. Further, Figs. 11(a,b) refer to the specific COS preparation and not to any microsomal preparation as required by the claims.